81 related articles for article (PubMed ID: 20571236)
1. Serum interleukin-8 and insulin like growth factor-1 in Egyptian bladder cancer patients.
Mahmoud MA; Ali MH; Hassoba HM; Elhadidy GS
Cancer Biomark; 2010; 6(2):105-10. PubMed ID: 20571236
[TBL] [Abstract][Full Text] [Related]
2. Possible contribution of serum activin A and IGF-1 in the development of hepatocellular carcinoma in Egyptian patients suffering from combined hepatitis C virus infection and hepatic schistosomiasis.
Elsammak MY; Amin GM; Khalil GM; Ragab WS; Abaza MM
Clin Biochem; 2006 Jun; 39(6):623-9. PubMed ID: 16624274
[TBL] [Abstract][Full Text] [Related]
3. Serum levels of vascular endothelial growth factor as a prognostic factor in bladder cancer.
Bernardini S; Fauconnet S; Chabannes E; Henry PC; Adessi G; Bittard H
J Urol; 2001 Oct; 166(4):1275-9. PubMed ID: 11547057
[TBL] [Abstract][Full Text] [Related]
4. Analysis of insulin like growth factor 1 and insulin like growth factor binding protein 3 levels in bronchoalveolar lavage fluid and serum of patients with lung cancer.
Unsal E; Köksal D; Yurdakul AS; Atikcan S; Cinaz P
Respir Med; 2005 May; 99(5):559-65. PubMed ID: 15823452
[TBL] [Abstract][Full Text] [Related]
5. Serum insulin-like growth factor is not elevated in patients with early B-cell chronic lymphocytic leukemia but is still a prognostic factor for disease progression.
Molica S; Vitelli G; Mirabelli R; Digiesu G; Giannarelli D; Cuneo A; Ribatti D; Vacca A
Eur J Haematol; 2006 Jan; 76(1):51-7. PubMed ID: 16343271
[TBL] [Abstract][Full Text] [Related]
6. Plasma levels of insulin-like growth factor-1 and binding protein-3, and their association with bladder cancer risk.
Zhao H; Grossman HB; Spitz MR; Lerner SP; Zhang K; Wu X
J Urol; 2003 Feb; 169(2):714-7. PubMed ID: 12544349
[TBL] [Abstract][Full Text] [Related]
7. Elevated serum insulin-like growth factor (IGF)-II and IGF binding protein-2 in patients with colorectal cancer.
Renehan AG; Jones J; Potten CS; Shalet SM; O'Dwyer ST
Br J Cancer; 2000 Nov; 83(10):1344-50. PubMed ID: 11044360
[TBL] [Abstract][Full Text] [Related]
8. Determination of diagnostic and prognostic values of urinary interleukin-8, tumor necrosis factor-alpha, and leukocyte arylsulfatase-A activity in patients with bladder cancer.
Koçak H; Oner-Iyidoğan Y; Koçak T; Oner P
Clin Biochem; 2004 Aug; 37(8):673-8. PubMed ID: 15302609
[TBL] [Abstract][Full Text] [Related]
9. Serum measurements of testosterone, insulin-like growth factor 1, and insulin-like growth factor binding protein-3 in the diagnosis of prostate cancer among Korean men.
Hong SK; Han BK; Jeong JS; Jeong SJ; Moon KH; Byun SS; Lee SE
Asian J Androl; 2008 Mar; 10(2):207-13. PubMed ID: 18097534
[TBL] [Abstract][Full Text] [Related]
10. Tissue polypeptide antigen (TPA) in comparison with mutations of tumour suppressor gene P53 (TP53) in patients with bladder cancer.
Ecke TH; Lenk SV; Schlechte HH; Loening SA
Anticancer Res; 2003; 23(2A):957-62. PubMed ID: 12820330
[TBL] [Abstract][Full Text] [Related]
11. [Detection of serum levels of MMP-9 and VEGF in patients with bladder cancer].
Guan KP; Hou SK; Yan Z; Ye HY
Zhonghua Wai Ke Za Zhi; 2003 Jun; 41(6):430-2. PubMed ID: 12895351
[TBL] [Abstract][Full Text] [Related]
12. Monocyte tissue factor levels in cancer patients.
Lwaleed BA; Francis JL; Chisholm M
Saudi Med J; 2000 Aug; 21(8):722-9. PubMed ID: 11423883
[TBL] [Abstract][Full Text] [Related]
13. Effect of vascular endothelial growth factor and its receptor inhibitor on proliferation and invasion in bladder cancer.
Nakanishi R; Oka N; Nakatsuji H; Koizumi T; Sakaki M; Takahashi M; Fukumori T; Kanayama HO
Urol Int; 2009; 83(1):98-106. PubMed ID: 19641368
[TBL] [Abstract][Full Text] [Related]
14. Preoperative plasma levels of interleukin-6 and its soluble receptor predict disease recurrence and survival of patients with bladder cancer.
Andrews B; Shariat SF; Kim JH; Wheeler TM; Slawin KM; Lerner SP
J Urol; 2002 Mar; 167(3):1475-81. PubMed ID: 11832773
[TBL] [Abstract][Full Text] [Related]
15. Serum levels of interleukin-18 (IL-18) and soluble interleukin-2 receptor (sIL-2R) in lung cancer.
Naumnik W; Chyczewska E; Kovalchuk O; Tałałaj J; Izycki T; Panek B
Rocz Akad Med Bialymst; 2004; 49():246-51. PubMed ID: 15631351
[TBL] [Abstract][Full Text] [Related]
16. Measurement of insulin-like growth factor axis does not enhance specificity of PSA-based prostate cancer screening.
Oliver SE; Holly J; Peters TJ; Donovan J; Persad R; Gillatt D; Pearce A; Hamdy FC; Neal DE; Gunnell D
Urology; 2004 Aug; 64(2):317-22. PubMed ID: 15302487
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of serum osteoprotegerin levels in patients with bladder carcinoma.
Mizutani Y; Matsubara H; Yamamoto K; Nan Li Y; Mikami K; Okihara K; Kawauchi A; Bonavida B; Miki T
Cancer; 2004 Oct; 101(8):1794-802. PubMed ID: 15386310
[TBL] [Abstract][Full Text] [Related]
18. [Association of insulin, insulin-like growth factor and insulin-like growth factor binding proteins with the risk of colorectal cancer].
Jiang B; Liu DB; Zhang X; DU LL; Han CZ
Zhonghua Wei Chang Wai Ke Za Zhi; 2009 May; 12(3):264-8. PubMed ID: 19434535
[TBL] [Abstract][Full Text] [Related]
19. Serum and urine levels of interleukin-8 in patients with non-Hodgkin's lymphoma.
Lee HL; Eom HS; Yun T; Kim HJ; Park WS; Nam BH; Moon-Woo S; Lee DH; Kong SY
Cytokine; 2008 Jul; 43(1):71-5. PubMed ID: 18502145
[TBL] [Abstract][Full Text] [Related]
20. Low serum insulin-like growth factor 1 (IGF-1): a significant association with prostate cancer.
Baffa R; Reiss K; El-Gabry EA; Sedor J; Moy ML; Shupp-Byrne D; Strup SE; Hauck WW; Baserga R; Gomella LG
Tech Urol; 2000 Sep; 6(3):236-9. PubMed ID: 10963500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]